FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
By T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J. Raoul, S. Gourgou-Bourgade, C. de la Fouchardière and 10 more. New England Journal of Medicine, 2011
6,730 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/11e708851d64ab23f0cfec1c88af6f0d9e466a57
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
- N. Desai
- W. Hawkins
- R. Morgan
- E. Musgrove
- F. Balkwill
- Japanese Gastric Cancer Association
- J. Joyce
- Lisa M. Coussens
Citations in the corpus
- Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021, background): “001), in favor of the group receiving FOLFIRINOX.(119) Eligibility criteria for this trial, however, were stringent, limiting real-world generalizability.”
- A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy (2016, background): “FOLFIRINOX has been considered a standard treatment option for patients with metastatic pancreatic cancer.(5) However, patients who receive FOLFIRINOX may experience more severe side effects than those who receive gemcitabine alone, so this combination is usually given to patients who are healthy en”
- Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. (2011, background): “2 months of OS, and 1-year survival of 48% at the MTD is among the highest reported for a phase II study in patients with PDA, including the fluorouracil, leucovorin, irinotecan, and oxaliplatin regimen,(26) which in a recent randomized phase III trial produced significantly improved survival compar”
- nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. (2015, background): “KPS 90-100 n = 241 n = 241 KPS 70-80 n = 164† n = 146 Neutropenia All treated 297 (73) 43 (11) 101 (25) 107 (26) 46 (11) 225 (58) 35 (9) 86 (22) 83 (21) 21 (5) KPS 90-100 185 (77) 22 (9) 65 (27) 67 (28) 31 (13) 156 (65) 20 (8) 60 (25) 60 (25) 16 (7) KPS 70-80 112 (68) 21 (13) 36 (22) 40 (24) 15 (9) ”
- Whole genomes redefine the mutational landscape of pancreatic cancer (2015, background): “The majority of structural variants were intra-chromosomal (10,114) and were classified into 7 types: intra-chromosomal rearrangements (5,860), deletions (1,393), duplications (128), tandem duplications (179), inversions (1,629), foldback inversions (579) and amplified inversions (346); inter-chromo”